Edit Entry

Alan I. Green, M.D.

Department Chair
Chair and Professor of Psychiatry
Professor of Pharmacology & Toxicology
Chairman, Department of Psychiatry
Director, SYNERGY: Dartmouth Clinical and Translational Science Institute
Associate Dean for Clinical and Translational Science, Geisel School of Medicine at Dartmouth

Pharmacology & Toxicology

Columbia College, A.B. 1965
The Johns Hopkins University School of Medicine, M.D. 1969

Neuroscience Center at Dartmouth
New Hampshire-Dartmouth Psychiatric Research Center
Pharmacology and Toxicology Graduate Program
Program in Experimental and Molecular Medicine
Psychopharmacology Research Group

Geisel School of Medicine at Dartmouth, Department of Psychiatry

SYNERGY (Dartmouth Center for Clinical and Translational Science)

Neuroscience Center at Dartmouth

PEMM at Dartmouth

Contact Information:

Department of Psychiatry
Geisel School of Medicine at Dartmouth
DHMC 1 Medical Center Drive
Lebanon NH 03756

Office: Same
Phone: 603-650-7549
Fax: 603-650-8415
Email: alan.i.green@dartmouth.edu

Assistant: Rebecca K. Paquette
Asst. Phone: 603-650-7549
Asst. Email: rebecca.k.paquette@dartmouth.edu

Professional Interests:

Schizophrenia and comorbid substance use disorder: neuropharmacology, neuroimaging and treatment development
Medication development for addiction
Brain reward circuitry
Animal models
Early intervention in schizophrenia

Dr. Green's research program, which involves clinical and neurobiological studies of patients with schizophrenia, particularly those with co-occurring substance use disorders, medication development studies for patients with alcoholism, and studies of alcohol drinking animals, has been funded by a series of grants from NIH, NARSAD and industry. He and his colleagues have proposed a neurobiological model suggesting that co-occurring substance use disorder in patients with schizophrenia relates, at least in part, to deficiencies in dopamine-mediated brain reward circuits. Data from his group have suggested that the novel antipsychotic medication clozapine limits alcohol and other substance use in these patients; he has proposed that the unique effects of clozapine in these patients relates to the mechanism of action of the drug, including its effects in brain reward circuits. On-going studies are continuing to probe the optimal psychopharmacological strategies for patients with co-occurring disorders through clinical trials, neuroimaging studies in humans, and a series of pharmacologic, neuroimaging and neurostimulation investigations in animals.

Rotations and Thesis Projects:

1) Medication development for alcohol drinking in rodents.
2) Neuroimaging and brain reward circuitry in schizophrenia.

Grant Information:

R01DA032533 (Green) 07/15/2012 – 03/31/2017
Clozapine for cannabis use disorder in schizophrenia
This study aims primarily to determine the comparative ability of clozapine and risperidone to decrease cannabis use in patients with schizophrenia and cannabis use disorder. Other subsidiary aims will determine the comparative effects of these medications on psychiatric symptoms, neuropsychological functioning, and quality of life. Lastly, the study will explore whether patients with the val/val genotype at the COMT val158met locus are more likely to respond to clozapine than are those with the met/met or the val/met genotype.

R01DA034699 (Green) 09/01/2013 – 03/31/2019
Cannabis, schizophrenia and reward: self-medication and agonist treatment?
This study aims to assess the effects of cannabis and dronabinol on the brain reward circuit in individuals with schizophrenia and co-occurring cannabis use disorder as well as in those with cannabis use disorder alone.

1 UL1 TR001086-01 (Green) 09/26/2013 – 04/30/2018
SYNERGY| The Dartmouth Clinical and Translational Science Institute
Dartmouth SYNERGY seeks to promote and substantially strengthen Dartmouth's basic, clinical, translational and outcomes research potential.

3UL1TR001086-02S2 (Green) 09/20/2014 – 08/31/2015
Development of a Cross-CTSA IRB Reliance Program (National IRB Reliance Initiative)
This Supplement to Dartmouth provides for the creation of a national program of IRB Reliance across the CTSA network – with the intent of increasing the speed and efficiency of launching and monitoring multi-site clinical investigations.

3UL1TR001086-02S1 (Green) 09/05/2014 – 03/04/2015
Enhancing Clinical Research Professionals’ Training and Qualifications
This Supplement allows Dartmouth to participate in a national program to enhance training for Good Clinical Practice across the national CTSA consortium.

NCIG-006 (Green) 04/01/2015 – 03/22/2016
NIAAA/Fast-Track Drugs & Biologics, LLC
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT® (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
This study aims to assess the efficacy of gabapentin in the treatment of alcohol use disorder.

Courses Taught:

Graduate and Medical Pharmacology
Neuroscience of Psychiatric Disorders


Alan I. Green, M.D. is the Raymond Sobel Professor of Psychiatry, Professor of Pharmacology and Toxicology and Chairman of the Department of Psychiatry at Geisel School of Medicine at Dartmouth.
Director, Dartmouth SYNERGY, The Dartmouth Clinical and Translational Science Institute.

He received his B.A. from Columbia College and his M.D. degree from the Johns Hopkins University School of Medicine. Following an internship in medicine at the Beth Israel Hospital in Boston, he was a research associate at the National Institute of Mental Health and was Director of Biomedical Research at the Special Action Office for Drug Abuse Prevention in the Executive Office of the President. He did his psychiatry residency and a clinical research fellowship at the Harvard-based Massachusetts Mental Health Center. He joined the Harvard faculty in 1984 and was Director of the Commonwealth Research Center at Harvard Medical School from 1987 until 2002. He joined the Geisel School of Medicine's Department of Psychiatry as Professor and Chairman in November 2002, and he became Director of Dartmouth SYNERGY in 2012. He has been a highly productive and active investigator, has received peer-reviewed funding throughout his career, has mentored over 30 trainees, and is the author of more than 300 papers and abstracts.

Mentoring Information:

Dr. Green has been the primary research mentor for over 30 predoctoral and postdoctoral trainees. At present, he is the primary mentor for two junior investigators, two post-doctoral research fellows, and five undergraduates.

Selected Publications:


  • Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research. 2004; 128:9-20. (view details on MedLine)

  • Roth R, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism? Curr Psychiatry Rep. 2005; 7(4):283-91. (view details on MedLine)

  • Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB, HGDH Study Group. Olanzapine and haloperidol in first-episode psychosis: Two year data. Schizophrenia Research. 2006; 86(1-3):234-243. (view details on MedLine)

  • Green AI, Noordsy DL, Brunette MF, O'Keefe C Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 2008; 34(1):61-71. (view details on MedLine)

  • Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Seidman LJ. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences of the U S A. 2009 Jan 27;106(4):1279-84. (view details on MedLine)

  • Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology, 2010: 58(2): 351-356. (view details on MedLine)

  • Chau DT, Ahmed J, Wang TT, Xie H, Dawson R, Green AI. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology, 2011: 61(4): 646-652. (view details on MedLine)

  • Gulick D, Chau DT, Khokhar JY, Dawson R, Green AI. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry Research, 2014. 218(3):329-34. (view details on MedLine)

  • Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired Functional Connectivity of Brain Reward Circuitry in Patients with Schizophrenia and Cannabis Use Disorder: Effects of Cannabis and THC. Schizophrenia Research. 2014. 158(1-3):176-182 (view details on MedLine)

  • Green AI, Brunette MF, Dawson R, Buckley P, Hafez H, Herz M, Narasimhan M, Noordsy D, O’Keefe C, Sommi RW, Weeks M. Long-acting Injectable vs. Oral Risperidone for Schizophrenia and Co-occurring Alcohol Disorder: A Randomized Trial. The Journal of Clinical Psychiatry, In Press. September, 2015.